{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T06:55:46Z","timestamp":1773557746462,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T00:00:00Z","timestamp":1463443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T00:00:00Z","timestamp":1463443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Early detection of dementia in Parkinson disease is a prerequisite for preventive therapeutic approaches. Modified serpinA1 in cerebrospinal fluid (CSF) was suggested as an early biomarker for differentiation between Parkinson patients with (PDD) or without dementia (PD). Within this study we aimed to further explore the diagnostic value of serpinA1. We applied a newly developed nanoscale method for the detection of serpinA1 based on automated capillary isoelectric focusing (CIEF). A clinical sample of 102 subjects including neurologically healthy controls (CON), PD and PDD patients was investigated. Seven serpinA1 isoforms of different charge were detected in CSF from all three diagnostic groups. The mean CSF signals of the most acidic serpinA1 isoform differed significantly (p\u2009&lt;\u20090.01) between PDD (n\u2009=\u200929) and PD (n\u2009=\u200937) or CON (n\u2009=\u200936). Patients above the cut-off of 6.4 have a more than six times higher risk for an association with dementia compared to patients below the cut off. We propose this serpinA1 CIEF-immunoassay as a novel tool in predicting cognitive impairment in PD patients and therefore for patient stratification in therapeutic trials.<\/jats:p>","DOI":"10.1038\/srep26145","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T09:16:49Z","timestamp":1463476609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Modified serpinA1 as risk marker for Parkinson\u2019s disease dementia: Analysis of baseline data"],"prefix":"10.1038","volume":"6","author":[{"given":"Steffen","family":"Halbgebauer","sequence":"first","affiliation":[]},{"given":"Magdalena","family":"Nagl","sequence":"additional","affiliation":[]},{"given":"Hans","family":"Klafki","sequence":"additional","affiliation":[]},{"given":"Ute","family":"Hau\u00dfmann","sequence":"additional","affiliation":[]},{"given":"Petra","family":"Steinacker","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Oeckl","sequence":"additional","affiliation":[]},{"given":"Jan","family":"Kassubek","sequence":"additional","affiliation":[]},{"given":"Elmar","family":"Pinkhardt","sequence":"additional","affiliation":[]},{"given":"Albert C.","family":"Ludolph","sequence":"additional","affiliation":[]},{"given":"Hilkka","family":"Soininen","sequence":"additional","affiliation":[]},{"given":"Sanna-Kaisa","family":"Herukka","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,5,17]]},"reference":[{"key":"BFsrep26145_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau, L. M. & Breteler, M. M. Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5, 525\u2013535, doi: 10.1016\/S1474-4422(06)70471-9 (2006).","journal-title":"Lancet Neurol"},{"key":"BFsrep26145_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan, I. et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27, 349\u2013356, doi: 10.1002\/mds.24893 (2012).","journal-title":"Mov Disord"},{"key":"BFsrep26145_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archneur.60.3.387","volume":"60","author":"D Aarsland","year":"2003","unstructured":"Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A. & Kragh-Sorensen, P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60, 387\u2013392 (2003).","journal-title":"Arch Neurol"},{"key":"BFsrep26145_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","volume":"8","author":"KR Chaudhuri","year":"2009","unstructured":"Chaudhuri, K. R. & Schapira, A. H. Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8, 464\u2013474, doi: 10.1016\/S1474-4422(09)70068-7 (2009).","journal-title":"Lancet Neurol"},{"key":"BFsrep26145_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2165\/00002512-200623100-00004","volume":"23","author":"A Rongve","year":"2006","unstructured":"Rongve, A. & Aarsland, D. Management of Parkinson\u2019s disease dementia : practical considerations. Drugs Aging 23, 807\u2013822 (2006).","journal-title":"Drugs Aging"},{"key":"BFsrep26145_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1001\/archneur.1997.00550150024011","volume":"54","author":"ED Louis","year":"1997","unstructured":"Louis, E. D., Marder, K., Cote, L., Tang, M. & Mayeux, R. Mortality from Parkinson disease. Arch Neurol 54, 260\u2013264 (1997).","journal-title":"Arch Neurol"},{"key":"BFsrep26145_CR7","doi-asserted-by":"publisher","first-page":"e48783","DOI":"10.1371\/journal.pone.0048783","volume":"7","author":"S Jesse","year":"2012","unstructured":"Jesse, S. et al. Differential sialylation of serpin A1 in the early diagnosis of Parkinson\u2019s disease dementia. PLoS One 7, e48783, doi: 10.1371\/journal.pone.0048783 (2012).","journal-title":"PLoS One"},{"key":"BFsrep26145_CR8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1084\/jem.20072080","volume":"205","author":"B Gooptu","year":"2008","unstructured":"Gooptu, B. & Lomas, D. A. Polymers and inflammation: disease mechanisms of the serpinopathies. J Exp Med 205, 1529\u20131534, doi: 10.1084\/jem.20072080 (2008).","journal-title":"J Exp Med"},{"key":"BFsrep26145_CR9","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1021\/cr010170+","volume":"102","author":"PG Gettins","year":"2002","unstructured":"Gettins, P. G. Serpin structure, mechanism and function. Chem Rev 102, 4751\u20134804 (2002).","journal-title":"Chem Rev"},{"key":"BFsrep26145_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1586\/ern.09.50","volume":"9","author":"DD Truong","year":"2009","unstructured":"Truong, D. D. & Wolters, E. C. Recognition and management of Parkinson\u2019s disease during the premotor (prodromal) phase. Expert Rev Neurother 9, 847\u2013857, doi: 10.1586\/ern.09.50 (2009).","journal-title":"Expert Rev Neurother"},{"key":"BFsrep26145_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/brain\/awh067","volume":"127","author":"T Foltynie","year":"2004","unstructured":"Foltynie, T., Brayne, C. E., Robbins, T. W. & Barker, R. A. The cognitive ability of an incident cohort of Parkinson\u2019s patients in the UK. The CamPaIGN study. Brain 127, 550\u2013560, doi: 10.1093\/brain\/awh067 (2004).","journal-title":"Brain"},{"key":"BFsrep26145_CR12","doi-asserted-by":"publisher","first-page":"S358","DOI":"10.1002\/mds.21677","volume":"22","author":"N Caballol","year":"2007","unstructured":"Caballol, N., Marti, M. J. & Tolosa, E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 22, Suppl 17, S358\u2013366, doi: 10.1002\/mds.21677 (2007).","journal-title":"Mov Disord"},{"key":"BFsrep26145_CR13","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1212\/01.wnl.0000338632.00552.cb","volume":"72","author":"D Aarsland","year":"2009","unstructured":"Aarsland, D., Bronnick, K., Larsen, J. P., Tysnes, O. B. & Alves, G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72, 1121\u20131126, doi: 10.1212\/01.wnl.0000338632.00552.cb (2009).","journal-title":"Neurology"},{"key":"BFsrep26145_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord 23, 837\u2013844, doi: 10.1002\/mds.21956 (2008).","journal-title":"Mov Disord"},{"key":"BFsrep26145_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.neulet.2008.11.015","volume":"450","author":"A Ohrfelt","year":"2009","unstructured":"Ohrfelt, A. et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450, 332\u2013335, doi: 10.1016\/j.neulet.2008.11.015 (2009).","journal-title":"Neurosci Lett"},{"key":"BFsrep26145_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3233\/JAD-2009-0955","volume":"16","author":"PE Spies","year":"2009","unstructured":"Spies, P. E., Melis, R. J., Sjogren, M. J., Rikkert, M. G. & Verbeek, M. M. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J Alzheimers Dis 16, 363\u2013369, doi: 10.3233\/JAD-2009-0955 (2009).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep26145_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/JAD-2010-100186","volume":"22","author":"FE Reesink","year":"2010","unstructured":"Reesink, F. E. et al. CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer\u2019s disease. J Alzheimers Dis 22, 87\u201395, doi: 10.3233\/JAD-2010-100186 (2010).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep26145_CR18","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/mds.23670","volume":"26","author":"L Parnetti","year":"2011","unstructured":"Parnetti, L. et al. Cerebrospinal fluid Tau\/alpha-synuclein ratio in Parkinson\u2019s disease and degenerative dementias. Mov Disord 26, 1428\u20131435, doi: 10.1002\/mds.23670 (2011).","journal-title":"Mov Disord"},{"key":"BFsrep26145_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","volume":"10","author":"B Mollenhauer","year":"2011","unstructured":"Mollenhauer, B. et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10, 230\u2013240, doi: 10.1016\/S1474-4422(11)70014-X (2011).","journal-title":"Lancet Neurol"},{"key":"BFsrep26145_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","volume":"213","author":"B Mollenhauer","year":"2008","unstructured":"Mollenhauer, B. et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213, 315\u2013325, doi: 10.1016\/j.expneurol.2008.06.004 (2008).","journal-title":"Exp Neurol"},{"key":"BFsrep26145_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","volume":"349","author":"T Tokuda","year":"2006","unstructured":"Tokuda, T. et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson\u2019s disease. Biochem Biophys Res Commun 349, 162\u2013166, doi: 10.1016\/j.bbrc.2006.08.024 (2006).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep26145_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/nature07394","volume":"455","author":"M Yamasaki","year":"2008","unstructured":"Yamasaki, M., Li, W., Johnson, D. J. & Huntington, J. A. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 455, 1255\u20131258, doi: 10.1038\/nature07394 (2008).","journal-title":"Nature"},{"key":"BFsrep26145_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0022-2836(02)01088-4","volume":"324","author":"GL Devlin","year":"2002","unstructured":"Devlin, G. L., Chow, M. K., Howlett, G. J. & Bottomley, S. P. Acid Denaturation of alpha1-antitrypsin: characterization of a novel mechanism of serpin polymerization. J Mol Biol 324, 859\u2013870 (2002).","journal-title":"J Mol Biol"},{"key":"BFsrep26145_CR24","first-page":"160","volume":"65","author":"KF Kok","year":"2007","unstructured":"Kok, K. F. et al. Heterozygous alpha-I antitrypsin deficiency as a co-factor in the development of chronic liver disease: a review. Neth J Med 65, 160\u2013166 (2007).","journal-title":"Neth J Med"},{"key":"BFsrep26145_CR25","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1002\/j.1460-2075.1996.tb00657.x","volume":"15","author":"T Osterwalder","year":"1996","unstructured":"Osterwalder, T., Contartese, J., Stoeckli, E. T., Kuhn, T. B. & Sonderegger, P. Neuroserpin, an axonally secreted serine protease inhibitor. EMBO J 15, 2944\u20132953 (1996).","journal-title":"EMBO J"},{"key":"BFsrep26145_CR26","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/S0002-9440(10)65510-1","volume":"155","author":"RL Davis","year":"1999","unstructured":"Davis, R. L. et al. Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol 155, 1901\u20131913, doi: 10.1016\/S0002-9440(10)65510-1 (1999).","journal-title":"Am J Pathol"},{"key":"BFsrep26145_CR27","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1212\/01.wnl.0000271077.82508.a0","volume":"69","author":"HM Nielsen","year":"2007","unstructured":"Nielsen, H. M. et al. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69, 1569\u20131579, doi: 10.1212\/01.wnl.0000271077.82508.a0 (2007).","journal-title":"Neurology"},{"key":"BFsrep26145_CR28","doi-asserted-by":"publisher","first-page":"121ra120","DOI":"10.1126\/scitranslmed.3002566","volume":"4","author":"Y Wang","year":"2012","unstructured":"Wang, Y. et al. Phosphorylated alpha-synuclein in Parkinson\u2019s disease. Sci Transl Med 4, 121ra120, doi: 10.1126\/scitranslmed.3002566 (2012).","journal-title":"Sci Transl Med"},{"key":"BFsrep26145_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0014-5793(02)03487-7","volume":"530","author":"F Liu","year":"2002","unstructured":"Liu, F., Iqbal, K., Grundke-Iqbal, I. & Gong, C. X. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett 530, 209\u2013214 (2002).","journal-title":"FEBS Lett"},{"key":"BFsrep26145_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/mas.20221","volume":"29","author":"H Hwang","year":"2010","unstructured":"Hwang, H. et al. Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev 29, 79\u2013125, doi: 10.1002\/mas.20221 (2010).","journal-title":"Mass Spectrom Rev"},{"key":"BFsrep26145_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0014-5793(02)02228-7","volume":"512","author":"F Liu","year":"2002","unstructured":"Liu, F. et al. Role of glycosylation in hyperphosphorylation of tau in Alzheimer\u2019s disease. FEBS Lett 512, 101\u2013106 (2002).","journal-title":"FEBS Lett"},{"key":"BFsrep26145_CR32","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1073\/pnas.1507329112","volume":"112","author":"HY Yen","year":"2015","unstructured":"Yen, H. Y. et al. Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition. Proc Natl Acad Sci USA 112, 6955\u20136960, doi: 10.1073\/pnas.1507329112 (2015).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep26145_CR33","doi-asserted-by":"publisher","first-page":"11332","DOI":"10.1073\/pnas.1107385108","volume":"108","author":"YC Liu","year":"2011","unstructured":"Liu, Y. C. et al. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci USA 108, 11332\u201311337, doi: 10.1073\/pnas.1107385108 (2011).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep26145_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55, 181\u2013184 (1992).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFsrep26145_CR35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427\u2013442 (1967).","journal-title":"Neurology"},{"key":"BFsrep26145_CR36","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre, M. et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord 22, 1689\u20131707, quiz 1837, doi: 10.1002\/mds.21507 (2007).","journal-title":"Mov Disord"},{"key":"BFsrep26145_CR37","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/j.1532-5415.1990.tb03461.x","volume":"38","author":"PA Parmelee","year":"1990","unstructured":"Parmelee, P. A. & Katz, I. R. Geriatric depression scale. J Am Geriatr Soc 38, 1379 (1990).","journal-title":"J Am Geriatr Soc"},{"key":"BFsrep26145_CR38","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1002\/pmic.200800375","volume":"8","author":"P Brechlin","year":"2008","unstructured":"Brechlin, P. et al. Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 8, 4357\u20134366, doi: 10.1002\/pmic.200800375 (2008).","journal-title":"Proteomics"},{"key":"BFsrep26145_CR39","doi-asserted-by":"publisher","first-page":"16153","DOI":"10.1073\/pnas.0607973103","volume":"103","author":"RA O\u2019Neill","year":"2006","unstructured":"O\u2019Neill, R. A. et al. Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc Natl Acad Sci USA 103, 16153\u201316158, doi: 10.1073\/pnas.0607973103 (2006).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep26145_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/elps.201400339","volume":"36","author":"S Halbgebauer","year":"2015","unstructured":"Halbgebauer, S. et al. Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands. Electrophoresis 36, 355\u2013362, doi: 10.1002\/elps.201400339 (2015).","journal-title":"Electrophoresis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep26145","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep26145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep26145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:57:03Z","timestamp":1672844223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep26145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,19]]}},"alternative-id":["BFsrep26145"],"URL":"https:\/\/doi.org\/10.1038\/srep26145","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,17]]},"assertion":[{"value":"15 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26145"}}